Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)

por Masucci, Lisa, Beca, Jaclyn, Sabharwal, Mona, Hoch, Jeffrey S.
Publicado 2017

Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?

por Hoch, Jeffrey S., Beca, Jaclyn, Sabharwal, Mona, Livingstone, Scott W., Fields, Anthony L. A.
Publicado 2015

Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?

por Cheung, Matthew C, Chan, Kelvin KW, Sabharwal, Mona, Fields, Anthony, Chambers, Alexandra, Evans, William K
Publicado 2017

The impact of pricing strategy on the costs of oral anti‐cancer drugs

por Truong, Judy, Chan, Kelvin K. W., Mai, Helen, Chambers, Alexandra, Sabharwal, Mona, Trudeau, Maureen E., Cheung, Matthew C.
Publicado 2019